ES2612945T3 - Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula - Google Patents

Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula Download PDF

Info

Publication number
ES2612945T3
ES2612945T3 ES10713874.5T ES10713874T ES2612945T3 ES 2612945 T3 ES2612945 T3 ES 2612945T3 ES 10713874 T ES10713874 T ES 10713874T ES 2612945 T3 ES2612945 T3 ES 2612945T3
Authority
ES
Spain
Prior art keywords
amino acid
cyaa
polypeptide
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10713874.5T
Other languages
English (en)
Spanish (es)
Inventor
Peter Sebo
Adriana Osickova
Jiri Masin
Catherine Fayolle
Jan Krusek
Marek Basler
Claude Leclerc
Radim Osicka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inst Of Physiology Of As Cr V V I
Institute of Microbiology CAS
Institute of Physiology CAS
Institut Pasteur
Original Assignee
Inst Of Physiology Of As Cr V V I
Institute of Microbiology CAS
Institute of Physiology CAS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP09155929.4A external-priority patent/EP2233569B1/en
Priority claimed from US12/409,324 external-priority patent/US8017132B2/en
Application filed by Inst Of Physiology Of As Cr V V I, Institute of Microbiology CAS, Institute of Physiology CAS, Institut Pasteur filed Critical Inst Of Physiology Of As Cr V V I
Application granted granted Critical
Publication of ES2612945T3 publication Critical patent/ES2612945T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
ES10713874.5T 2009-03-23 2010-03-23 Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula Active ES2612945T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US409324 2009-03-23
EP09155929 2009-03-23
EP09155929.4A EP2233569B1 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
US12/409,324 US8017132B2 (en) 2009-03-23 2009-03-23 Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
PCT/EP2010/053795 WO2010136231A1 (en) 2009-03-23 2010-03-23 MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL

Publications (1)

Publication Number Publication Date
ES2612945T3 true ES2612945T3 (es) 2017-05-19

Family

ID=42224889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10713874.5T Active ES2612945T3 (es) 2009-03-23 2010-03-23 Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula

Country Status (7)

Country Link
EP (1) EP2411513B1 (cg-RX-API-DMAC7.html)
JP (1) JP5770711B2 (cg-RX-API-DMAC7.html)
CN (2) CN102439146A (cg-RX-API-DMAC7.html)
CA (1) CA2755694A1 (cg-RX-API-DMAC7.html)
ES (1) ES2612945T3 (cg-RX-API-DMAC7.html)
RU (1) RU2585216C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010136231A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP2975120A1 (en) 2014-07-17 2016-01-20 Institut Pasteur Monomeric and functional adenylate cyclase CyaA toxin
EP3323426A1 (en) * 2016-11-17 2018-05-23 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
WO2018091613A1 (en) * 2016-11-17 2018-05-24 Ecole Nationale Vétérinaire de Toulouse Immunogenic and vaccine compositions for use against bordetella bronchiseptica infection
EP3381931A1 (en) * 2017-03-29 2018-10-03 Mikrobiologicky ustav AV CR, v.v.i. Adenylate cyclase toxoid with reduced cytolytic activity
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86583A0 (en) * 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
FR2638169B1 (fr) * 1988-10-25 1991-01-11 Pasteur Institut Derives d'adenyl cyclase et leurs utilisations biologiques
ATE368113T1 (de) 1992-04-21 2007-08-15 Pasteur Institut Rekombinante mutanten zur induktion spezifischer immunantworten
FR2805544B1 (fr) * 2000-02-28 2004-07-16 Pasteur Institut Adenylcyclase recombinante et procede de tri de molecules a activite proteolytique utilisant cette adenylcyclase
ES2331348T3 (es) * 2000-09-15 2009-12-30 Pasteur Institut Vectores proteinicos para el suministro de moleculas a las celulas que expresan cd11b.
EP1489092A1 (en) * 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
CA2542612A1 (en) * 2003-10-14 2005-04-21 Kingston Henry Gordon Mills Adenylate cyclase in the treatment and/or prophylaxis of immune-medicated disease
EP1576967B1 (en) * 2004-03-18 2007-09-12 Institut Pasteur Recombinant protein, carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof, therapeutic uses thereof

Also Published As

Publication number Publication date
CA2755694A1 (en) 2010-12-02
CN102439146A (zh) 2012-05-02
JP5770711B2 (ja) 2015-08-26
RU2011138706A (ru) 2013-04-27
RU2585216C2 (ru) 2016-05-27
CN105602924A (zh) 2016-05-25
JP2012521207A (ja) 2012-09-13
EP2411513B1 (en) 2016-11-09
EP2411513A1 (en) 2012-02-01
WO2010136231A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
ES2612945T3 (es) Polipéptidos de CyaA mutantes y derivados polipeptídicos adecuados para el suministro de moléculas inmunogénicas en una célula
CA2674269C (en) Three component glycolipopeptides
US9708596B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
JP2018510215A (ja) 神経膠芽腫を治療するための細胞透過性ペプチド、カーゴ、及びｔｌｒペプチドアゴニストを含む新規複合体
US11638753B2 (en) Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11759508B2 (en) Antigenic peptides for treatment of B-cell malignancy
KR20160088323A (ko) S. 뉴모니에(S. pneumoniae)에 대항하는 보호성 프롤린-풍부한 펩티드
EP4045150B1 (en) Immunogenic compounds for treatment of adrenal cancer
US20240209325A1 (en) Cancer prophylaxis and therapy using targeted viral nanoparticles
CN103957943A (zh) 纳米颗粒肿瘤疫苗
US20160222362A1 (en) Target-Specific Double-Mutant Fusion Protein and Preparation Process Therefor
US8017132B2 (en) Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell
JP2006512049A (ja) 免疫原コンジュゲート
JP2015515276A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム
WO2019120063A1 (zh) 低pH插入肽及其组合物
JP6758022B2 (ja) 血管内皮細胞増殖因子受容体阻害ペプチド
JP2022544407A (ja) 免疫原性組成物
US20210277077A1 (en) Recombinant transmembrane domain-deficient sting as biomimetic protein carrier for cgamp enhanced cancer immunotherapy
US10920212B2 (en) Monomeric and functional adenylate cyclase CyaA toxin
WO2017142988A1 (en) Methods and compositions for treating melanoma
JP2018134074A (ja) ヘパリン結合性赤血球凝集素（ｈｂｈａ）融合タンパク質とその用途をコードする組換え型マイコバクテリウム